Form Ds provide information on individual, unregistered securities offerings.
Search by Recipient Name or Primary Issuer:
| Recipient | CRD | Primary Issuer | CIK | Filing Date | Form Type | Total Offering Amount | Total Amount Sold |
|---|---|---|---|---|---|---|---|
| CANTOR FITZGERALD & CO. | 134 | Cantor Commercial Real Estate Company, L.P. | 1498396 | 08/12/2010 | D | Indefinite | $432,000,000 |
| CANTOR FITZGERALD & CO. | 134 | Orchard Therapeutics plc | 1748907 | 02/24/2021 | D | $149,999,996 | $149,999,996 |
| CANTOR FITZGERALD & CO. | 134 | Verastem, Inc. | 1526119 | 03/06/2020 | D | $100,000,000 | $100,000,000 |
| CANTOR FITZGERALD & CO. | 134 | SELECTA BIOSCIENCES INC | 1453687 | 01/02/2020 | D | $70,000,000 | $70,000,000 |
| CANTOR FITZGERALD & CO. | 134 | CF Glenmuir Multifamily DST | 1872937 | 09/27/2021 | D | $86,100,000 | $67,664,789 |
| CANTOR FITZGERALD & CO. | 134 | X4 Pharmaceuticals, Inc | 1501697 | 06/01/2023 | D | $65,023,725 | $65,015,462 |
| CANTOR FITZGERALD & CO. | 134 | Lyra Therapeutics, Inc. | 1327273 | 06/09/2023 | D | $50,000,008 | $50,000,008 |
| CANTOR FITZGERALD & CO. | 134 | CF WAG MH, LLC | 1940970 | 08/03/2022 | D | $28,526,316 | $28,526,316 |
| CANTOR FITZGERALD & CO. | 134 | Exela Technologies, Inc. | 1620179 | 03/31/2021 | D | Indefinite | $26,762,502 |
| CANTOR FITZGERALD & CO. | 134 | Entasis Therapeutics Holdings Inc. | 1724344 | 09/10/2020 | D | $24,999,999 | $24,999,999 |